TAK - TAKEDA PHARMACEUTICAL CO LTD

QQQ $ 441.08 $ 0.62 (0.14 %)

DIA $ 393.28 $ 3.07 (0.79 %)

SPY $ 519.44 $ 1.99 (0.38 %)

TLT $ 90.54 $ 0.50 (0.56 %)

GLD $ 215.96 $ 1.26 (0.59 %)

Previous Close

$ 13.06

Open

$ 12.92

Bid

$ 13.34 x 300

Ask

$ 13.35 x 400

Day's Range

$ 12.78 - $ 13.44

52 Week Range

$ 13.01 - $ 17.12

Volume

1,562,818

Average Volume

Market Cap

22.13B

Beta (5Y Monthly)

$ 0.59

PE Ratio (TTM)

$ 9.27

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type	Report Link
No Data found

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

japans-takeda-pharma-outlines-900m-overhaul-to-boost-growth-as-2023-profit-fall-over-50

Japan's Takeda Pharma Outlines $900M Overh...
05/09/2024 17:46:46

Takeda Pharmaceutical (NYSE: TAK) reveals fiscal year 2023 results & restructuring plan. Revenue up 5.9%, net profit down 5...

Takeda 2024 Outlook: Expects Revenue Of ¥ ...
05/09/2024 06:41:51

FY2024 Outlook (Billion yen) FY2024 FORECAST FY2024 MANAGEMEN...

Takeda Pharmaceutical FY23 Core EPS ¥484 D...
05/09/2024 06:34:35

HUTCHMED Announces Positive CHMP Opinion F...
04/26/2024 12:36:52

— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer reg...

Takeda Receives Positive CHMP Opinion For ...
04/26/2024 12:32:57

− If Approved in the European Union, Fruquintinib Will Be the First Novel Targeted Therapy for Metastatic Colorectal Cancer Reg...

neurocrine-biosciences-says-treatment-can-alleviate-several-symptoms-associated-with-depressive-disorder

Neurocrine Biosciences Says Treatment Can ...
04/23/2024 17:28:11

Neurocrine Biosciences reports Phase 2 data for NBI-1065845 in major depressive disorder. Results show significant improvement ...

Reported Earlier, Takeda Announces U.S. FD...
04/19/2024 06:27:28

ENTYVIO is Now Available in the U.S. in Both IV and Subcutaneous Administrations for Maintenance Treatment of Adults with Moder...

Takeda Announces Approval Of ADZYNMA Intra...
03/26/2024 12:02:24

cTTP is an Ultra-rare Blood Clotting Disorder Associated with Life-Threatening Acute Events and Debilitating Chronic SymptomsAD...

Takeda Announces U.S. FDA Approval Of Supp...
03/19/2024 16:21:44

− ICLUSIG Becomes the First and Only Targeted Treatment Approved in the U.S. for Frontline Ph+ Acute Lymphoblastic Leukemia (AL...

CENTOGENE Extends Strategic Partnership Wi...
03/19/2024 10:32:07

Centogene N.V. (NASDAQ:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases...

Protagonist Therapeutics Closes Worldwide ...
03/18/2024 11:12:53

Takeda Announces Topline Results from Phas...
03/13/2024 12:06:56

Pre-Specified Interim Analysis Shows Positive Safety and Efficacy Results; Mezagitamab Safe and Well Tolerated Takeda Intend...

Takeda And Biological E. Limited Enter Str...
02/27/2024 07:30:26

Biological E. Limited (BE) to Manufacture Up to 50 Million Doses of QDENGA Per Year, Accelerating Takeda's Ability to Del...

fda-approves-takedas-eohilia-as-first-oral-treatment-for-inflammed-esophagus

FDA Approves Takeda's Eohilia As First Ora...
02/12/2024 17:17:23

Eohilia: FDA-approved oral therapy for EoE. Takeda's innovative 2mg/10mL stick packs available by February. Histologic remi...

FDA Approves Takeda's EOHILIA, The First A...
02/12/2024 13:00:58

— 12 Weeks of Treatment with EOHILIA May Address Significant Unmet Needs of Patients 11 Years of Age and Older— EoE Is a Chroni...

good-news-for-sleep-disorder-patients---takedas-therapy-shows-promise-in-mid-stage-study

Good News For Sleep Disorder Patients - Ta...
02/09/2024 16:45:55

Takeda's Phase 2b trial results for TAK-861, an oral orexin receptor 2 agonist, in narcolepsy type 1 patients. Global Phase...

Takeda Says It Does Not Plan To Advance TA...
02/08/2024 23:05:52

Takeda plans to initiate global Phase 3 trials of TAK-861 in NT1 rapidly in the first half of its fiscal year 2024.

Takeda Says Primary And Key Secondary Endp...
02/08/2024 23:02:53

The NT1 trial TAK-861-2001 evaluating TAK-861 in 112 patients demonstrated statistically significant and clinically meaningful ...

why-is-japanese-drugmaker-takeda-stock-trading-lower-today

Why Is Japanese Drugmaker Takeda Stock Tra...
02/01/2024 19:07:29

Takeda Pharmaceutical's Q3 2023 results: ¥235.9 billion core net profit, management changes, and a global collaboration dea...

Earnings Scheduled For February 1, 2024
02/01/2024 10:03:12

Companies Reporting Before The Bell • ING Groep (NYSE:ING) is expected to report earnings for its fourth quarter. • Shell (NY...